Literature DB >> 22158553

Novel molecular therapies for heritable skin disorders.

Jouni Uitto1, Angela M Christiano, W H Irwin McLean, John A McGrath.   

Abstract

Tremendous progress has been made in the past two decades in molecular genetics of heritable skin diseases, and pathogenic mutations have been identified in as many as 500 distinct human genes. This progress has resulted in improved diagnosis with prognostic implications, has refined genetic counseling, and has formed the basis for prenatal and presymptomatic testing and preimplantation genetic diagnosis. However, there has been relatively little progress in developing effective and specific treatments for these often devastating diseases. However, very recently, a number of novel molecular strategies, including gene therapy, cell-based approaches, and protein replacement therapy, have been explored for the treatment of these conditions. This overview will focus on the prototypic heritable blistering disorders, epidermolysis bullosa, and related keratinopathies, in which significant progress has been made recently toward treatment, and it will illustrate how some of the translational research therapies have already entered the clinical arena.

Entities:  

Mesh:

Year:  2011        PMID: 22158553      PMCID: PMC3572786          DOI: 10.1038/jid.2011.389

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  80 in total

Review 1.  The future is much closer collaboration between the pharmaceutical industry and academic medical centers.

Authors:  P Vallance; P Williams; C Dollery
Journal:  Clin Pharmacol Ther       Date:  2010-05       Impact factor: 6.875

2.  Animal models of epidermolysis bullosa: update 2010.

Authors:  Leena Bruckner-Tuderman; John A McGrath; E Clare Robinson; Jouni Uitto
Journal:  J Invest Dermatol       Date:  2010-06       Impact factor: 8.551

Review 3.  Animal models of epidermolysis bullosa.

Authors:  Ken Natsuga; Satoru Shinkuma; Wataru Nishie; Hiroshi Shimizu
Journal:  Dermatol Clin       Date:  2010-01       Impact factor: 3.478

Review 4.  Fibroblast-based cell therapy strategy for recessive dystrophic epidermolysis bullosa.

Authors:  W F Yan; Dédée F Murrell
Journal:  Dermatol Clin       Date:  2010-04       Impact factor: 3.478

Review 5.  Bone marrow stem cell therapy for recessive dystrophic epidermolysis bullosa.

Authors:  Maija Kiuru; Munenari Itoh; Mitchell S Cairo; Angela M Christiano
Journal:  Dermatol Clin       Date:  2010-04       Impact factor: 3.478

6.  Replenishment of type VII collagen and re-epithelialization of chronically ulcerated skin after intradermal administration of allogeneic mesenchymal stromal cells in two patients with recessive dystrophic epidermolysis bullosa.

Authors:  Paulette Conget; Fernando Rodriguez; Susanne Kramer; Carolina Allers; Valeska Simon; Francis Palisson; Sergio Gonzalez; Maria J Yubero
Journal:  Cytotherapy       Date:  2010-05       Impact factor: 5.414

7.  First-in-human mutation-targeted siRNA phase Ib trial of an inherited skin disorder.

Authors:  Sancy A Leachman; Robyn P Hickerson; Mary E Schwartz; Emily E Bullough; Stephen L Hutcherson; Kenneth M Boucher; C David Hansen; Mark J Eliason; G Susan Srivatsa; Douglas J Kornbrust; Frances Jd Smith; Wh Irwin McLean; Leonard M Milstone; Roger L Kaspar
Journal:  Mol Ther       Date:  2009-11-24       Impact factor: 11.454

Review 8.  Type VII collagen: the anchoring fibril protein at fault in dystrophic epidermolysis bullosa.

Authors:  Hye Jin Chung; Jouni Uitto
Journal:  Dermatol Clin       Date:  2010-01       Impact factor: 3.478

9.  Adenoviral gene delivery can reprogram human fibroblasts to induced pluripotent stem cells.

Authors:  Wenbo Zhou; Curt R Freed
Journal:  Stem Cells       Date:  2009-11       Impact factor: 6.277

10.  Telomere elongation in induced pluripotent stem cells from dyskeratosis congenita patients.

Authors:  Suneet Agarwal; Yuin-Han Loh; Erin M McLoughlin; Junjiu Huang; In-Hyun Park; Justine D Miller; Hongguang Huo; Maja Okuka; Rosana Maria Dos Reis; Sabine Loewer; Huck-Hui Ng; David L Keefe; Frederick D Goldman; Aloysius J Klingelhutz; Lin Liu; George Q Daley
Journal:  Nature       Date:  2010-02-17       Impact factor: 49.962

View more
  22 in total

1.  A living band-aid for epidermolysis bullosa.

Authors:  Jakub Tolar; Miroslav Tolar
Journal:  Blood Transfus       Date:  2015-01       Impact factor: 3.443

Review 2.  From marrow to matrix: novel gene and cell therapies for epidermolysis bullosa.

Authors:  Beau R Webber; Jakub Tolar
Journal:  Mol Ther       Date:  2015-03-24       Impact factor: 11.454

Review 3.  Laminin 332 in junctional epidermolysis bullosa.

Authors:  Dimitra Kiritsi; Cristina Has; Leena Bruckner-Tuderman
Journal:  Cell Adh Migr       Date:  2012-10-17       Impact factor: 3.405

4.  [New developments in hereditary blistering skin diseases].

Authors:  L Bruckner-Tuderman
Journal:  Hautarzt       Date:  2013-01       Impact factor: 0.751

Review 5.  Defining the extracellular matrix using proteomics.

Authors:  Adam Byron; Jonathan D Humphries; Martin J Humphries
Journal:  Int J Exp Pathol       Date:  2013-02-19       Impact factor: 1.925

Review 6.  Progress towards genetic and pharmacological therapies for keratin genodermatoses: current perspective and future promise.

Authors:  Jean Christopher Chamcheu; Gary S Wood; Imtiaz A Siddiqui; Deeba N Syed; Vaqar M Adhami; Joyce M Teng; Hasan Mukhtar
Journal:  Exp Dermatol       Date:  2012-07       Impact factor: 3.960

Review 7.  Pathogenesis-based therapies in ichthyoses.

Authors:  Joey E Lai-Cheong; Peter M Elias; Amy S Paller
Journal:  Dermatol Ther       Date:  2013 Jan-Feb       Impact factor: 2.851

Review 8.  Allogeneic blood and bone marrow cells for the treatment of severe epidermolysis bullosa: repair of the extracellular matrix.

Authors:  Jakub Tolar; John E Wagner
Journal:  Lancet       Date:  2013-10-05       Impact factor: 79.321

Review 9.  Modulating the stem cell niche for tissue regeneration.

Authors:  Steven W Lane; David A Williams; Fiona M Watt
Journal:  Nat Biotechnol       Date:  2014-08       Impact factor: 54.908

Review 10.  Molecular therapeutics for heritable skin diseases.

Authors:  Jouni Uitto
Journal:  J Invest Dermatol       Date:  2012-11-15       Impact factor: 8.551

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.